title: Synthesis, characterization, and preliminaryin vitrostudies of vanadium(IV) complexes with a Schiff base and thiosemicarbazones as mixed-ligands.
abstract: [VO(Sal-L-tryp)(H2O)]1(where sal-L-tryp =N-salicylidene-L-tryptophanate) was used as a precursor to produce the novel complexes, [VO(Sal-L-tryp)(MeATSC)].1.5C2H5OH2(where MeATSC = 9-Anthraldehyde-N(4)-methylthiosemicarbazone), [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O3(whereN-Ethhymethohcarbthio = (E)-N-ethyl-2-(4-hydroxy-3-methoxybenzylidene)hydrazinecarbothioamide), and [VO(Sal-L-tryp)(acetylethTSC)].C2H5OH4(where acetylethTSC = (E)-N-ethyl-2-(1-(thiazol-2-yl)ethylidene)hydrazinecarbothioamide), by reaction with the respective thiosemicarbazone. The chemical and structural properties of these ligands and complexes were characterised by elemental analysis, ESI MS, FT-IR, UV-visible, ESR,1H and13C NMR spectroscopy, and X-ray crystallography. DMSO and DMSO-d6solutions of compounds1-4were oxidised in air to produce vanadium(V) species which were verified by ESI MS and51V NMR spectroscopy. Anti-cancer properties of compounds2-4were examined with three colon cancer cell lines, HTC-116, Caco-2, and HT-29, and also with non-cancerous colonic myofibroblasts, CCD18-Co. Compounds2-3exhibited less inhibitory effects in the CCD-18Co cells, indicating a possible cytotoxic selectivity towards colon cancer cells. In general, those compounds which exhibited anti-proliferative activity on cancer cells, but did not affect non-cancerous cells, may have a potential in chemotherapy.
authors.affiliation: Department of Chemistry and Biochemistry, The University of Southern Mississippi, 118 College Drive, # 5043, Hattiesburg, Mississippi 39406-0001.
authors.forename: Nerissa A
authors.initials: NA
authors.lastname: Lewis
authors.forename: Fange
authors.initials: F
authors.lastname: Liu
authors.forename: Luke
authors.initials: L
authors.lastname: Seymour
authors.forename: Anthony
authors.initials: A
authors.lastname: Magnusen
authors.forename: Travis R
authors.initials: TR
authors.lastname: Erves
authors.forename: Jessa Faye
authors.initials: JF
authors.lastname: Arca
authors.forename: Floyd A
authors.initials: FA
authors.lastname: Beckford
authors.forename: Ramaiyer
authors.initials: R
authors.lastname: Venkatraman
authors.forename: Antonio
authors.initials: A
authors.lastname: González-Sarrías
authors.forename: Frank R
authors.initials: FR
authors.lastname: Fronczek
authors.forename: Don G
authors.initials: DG
authors.lastname: Vanderveer
authors.forename: Navindra P
authors.initials: NP
authors.lastname: Seeram
authors.forename: Aimin
authors.initials: A
authors.lastname: Liu
authors.forename: William L
authors.initials: WL
authors.lastname: Jarrett
authors.forename: Alvin A
authors.initials: AA
authors.lastname: Holder
keywords: 51V NMR; ESR spectroscopy; colorectal cancer; thiosemicarbazone; vanadium(IV); vanadium(V)
references.citation: Anticancer Agents Med Chem. 2010 May;10(4):312-23
references.pmid: 20380636
references.citation: Arch Pharm (Weinheim). 2007 Mar;340(3):117-26
references.pmid: 17315259
references.citation: Rev Physiol Biochem Pharmacol. 2003;146:1-54
references.pmid: 12605304
references.citation: Chem Rev. 1998 May 7;98(3):1171-1200
references.pmid: 11848929
references.citation: Methods Enzymol. 1997;277:319-43
references.pmid: 18488315
references.citation: Inorg Chem. 2004 Nov 15;43(23):7324-38
references.pmid: 15530082
references.citation: J Am Chem Soc. 2003 Oct 15;125(41):12606-14
references.pmid: 14531705
references.citation: Anticancer Drugs. 2000 Nov;11(10):849-58
references.pmid: 11142693
references.citation: Inorg Chem. 1997 Apr 9;36(8):1657-1668
references.pmid: 11669757
references.citation: Chem Commun (Camb). 2002 Feb 7;(3):212-3
references.pmid: 12120371
references.citation: Eur J Med Chem. 2011 Jan;46(1):150-9
references.pmid: 21112129
references.citation: Inorg Chem. 2007 Aug 6;46(16):6723-32
references.pmid: 17628058
references.citation: Inorg Chem. 1996 Oct 23;35(22):6466-6472
references.pmid: 11666794
references.citation: J Inorg Biochem. 2000 May 30;80(1-2):35-9
references.pmid: 10885461
references.citation: Inorg Chem. 2007 Dec 24;46(26):11112-21
references.pmid: 18020327
references.citation: Bioorg Med Chem. 2000 Jan;8(1):157-62
references.pmid: 10968274
references.citation: Chem Rev. 1999 Sep 8;99(9):2451-66
references.pmid: 11749486
references.citation: Dalton Trans. 2009 Mar 21;(11):1914-8
references.pmid: 19259560
references.citation: Dalton Trans. 2009 Dec 28;(48):10757-64
references.pmid: 20023905
references.citation: Inorg Chem. 2008 Nov 3;47(21):9848-56
references.pmid: 18823111
references.citation: Cancer Commun. 1991 Jul;3(7):207-12
references.pmid: 1867954
references.citation: Dalton Trans. 2010 Feb 7;39(5):1159-70
references.pmid: 20104335
references.citation: J Inorg Biochem. 2007 Mar;101(3):525-35
references.pmid: 17239442
references.citation: Inorg Chem. 2009 Jul 6;48(13):5790-6
references.pmid: 19449891
references.citation: Chem Rev. 1999 Sep 8;99(9):2511-34
references.pmid: 11749489
references.citation: J Ethnopharmacol. 2008 Oct 30;120(1):36-43
references.pmid: 18718517
references.citation: J Biol Inorg Chem. 2008 Jan;13(1):47-55
references.pmid: 17909866
references.citation: J Comput Chem. 2011 Oct;32(13):2822-35
references.pmid: 21735449
references.citation: J Inorg Biochem. 2005 Feb;99(2):443-51
references.pmid: 15621276
references.citation: Curr Pharm Des. 2003;9(25):2078-89
references.pmid: 14529417
references.citation: J Org Chem. 2010 May 7;75(9):2922-33
references.pmid: 20373768
references.citation: Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22
references.pmid: 18156677
references.citation: Expert Opin Investig Drugs. 2002 Dec;11(12):1829-36
references.pmid: 12457442
references.citation: Biochim Biophys Acta. 1986 Oct 29;884(1):84-92
references.pmid: 3021234
references.citation: Acta Crystallogr C. 2003 May;59(Pt 5):m190-2
references.pmid: 12743394
references.citation: Inorg Chem. 2002 Aug 26;41(17):4502-8
references.pmid: 12184768